HR 3666 114th Congress House Health Congressional oversight Department of Health and Human Services Executive agency funding and structure Immunology and vaccination Medical research Musculoskeletal and skin diseases National Institutes of Health (NIH) Research administration and funding

Scleroderma and Fibrosis Research Enhancement Act of 2015

Introduced: October 1, 2015 See on congress.gov

Everywhere this bill has been 3 steps

Introduced

In committee

Reported out

Passed House

Passed Senate

To President

Became law

Oct 2, 2015

Referred to the Subcommittee on Health.

Oct 1, 2015

Referred to the House Committee on Energy and Commerce.

Oct 1, 2015

Introduced in House

Plain-English summary Congressional Research Service

Scleroderma and Fibrosis Research Enhancement Act of 2015

This bill requires the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) to establish the National Commission on Scleroderma and Fibrosis Research. (Scleroderma and fibrosis are connective tissue conditions that cause hardening or scarring of skin and organs.)

The commission must develop a long-term, comprehensive plan for scleroderma and fibrosis research. The plan must: (1) prioritize research that has cross-cutting value and requires coordination across NIH, and (2) include specific steps for implementation of the research.

The commission must establish working groups to make research recommendations for the various organs and systems impacted by fibrotic illness.

The commission must be terminated not later than two years after establishment.

The NIAMS must create the Scleroderma and Fibrosis Working Group to oversee and assist with implementation of the long-term plan.

What's happening now October 2, 2015

Referred to the Subcommittee on Health.

Committees of jurisdiction 2